Debiopharm International SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH114705D
- Pages: 39
- September 2018
- Total Views:1152
- Region : Europe
- GlobalData
- Equity Research Report
Details
Summary
Debiopharm International SA (Debiopharm), a subsidiary of Debiopharm Group is a biopharmaceutical company that develops prescription drugs. The company offers a range of licensing and drug development solutions. It evaluates, searches, and in-licenses promising drug candidates for development. Debiopharm's products includes decapeptyl, eloxatin, pamorelin, trelstar, moapar and salvacyl among others. The company offer products for the treatment of in vitro fertilization, metastatic colorectal cancer, advanced prostate cancer, precocious puberty, endometriosis, liver cancer, pancreatic cancer, uterine fibroids, severe sexual deviations and other diseases. It also develops drugs for indications in the therapeutic areas of infectious diseases and orphan drugs. The company provides licensing of products to pharmaceutical companies for marketing and sales. Debiopharm is headquartered in Lausanne, Switzerland.
Debiopharm International SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Debiopharm International SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Debiopharm International SA, Medical Devices Deals, 2012 to YTD 2018 9
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Debiopharm International SA, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 12
Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 13
Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 14
Venture Financing 16
Spinomix Raises USD 3 Million In Series A Financing 16
Biocartis Raises USD 44.7 Million In Series D Financing 17
Partnerships 19
Debiopharm Partners with Merck and Pfizer 19
Debiopharm Enters into Distribution Agreement with Arbor Pharma 20
Debiopharm International Enters into Agreement with EORTC 21
United Labs Enters into Distribution Agreement with Debiopharm International 22
Debiopharm Enters into Agreement with Solid Biosciences 23
Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 24
Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 25
Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 26
Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 27
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 28
Licensing Agreements 29
Debiopharm International Enters into Licensing Agreement with Almac Discovery 29
Evotec Enters Into Licensing Agreement With Debiopharm 30
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 31
Shasun Pharma Enters Into Licensing Agreement With Debiopharm 32
Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 33
Debiopharm International SA-Key Competitors 34
Debiopharm International SA-Key Employees 35
Debiopharm International SA-Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Government and Public Interest 37
Jul 25, 2017: Debiopharm International Awarded USD 2.6 Million Grant from CARB-X to Support Development of Debio 1453 to Fight Drug Resistant Gonorrhea 37
Clinical Trials 38
Jan 10, 2017: Debiopharm International Announces positive Phase 2 Clinical Trial with Debio 1450 in ABSSSI patients 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39
List Of Figure
List of Figures
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Debiopharm International SA, Medical Devices Deals, 2012 to YTD 2018 9
List Of Table
List of Tables
Debiopharm International SA, Pharmaceuticals & Healthcare, Key Facts 2
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Debiopharm International SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Debiopharm International SA, Deals By Therapy Area, 2012 to YTD 2018 8
Debiopharm International SA, Medical Devices Deals, 2012 to YTD 2018 9
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 12
Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 13
Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 14
Spinomix Raises USD 3 Million In Series A Financing 16
Biocartis Raises USD 44.7 Million In Series D Financing 17
Debiopharm Partners with Merck and Pfizer 19
Debiopharm Enters into Distribution Agreement with Arbor Pharma 20
Debiopharm International Enters into Agreement with EORTC 21
United Labs Enters into Distribution Agreement with Debiopharm International 22
Debiopharm Enters into Agreement with Solid Biosciences 23
Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 24
Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 25
Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 26
Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 27
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 28
Debiopharm International Enters into Licensing Agreement with Almac Discovery 29
Evotec Enters Into Licensing Agreement With Debiopharm 30
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 31
Shasun Pharma Enters Into Licensing Agreement With Debiopharm 32
Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 33
Debiopharm International SA, Key Competitors 34
Debiopharm International SA, Key Employees 35
Debiopharm International SA, Subsidiaries 36
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Debiopharm International SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Debiopharm International SA (Debiopharm), a subsidiary of Debiopharm Group is a biopharmaceutical company that develops prescription drugs. The company offers a range of licensing and drug development solutions. It evaluates, searches, and in-licenses promising drug candidates for development. Debiopharm's products includes decapeptyl, eloxatin, pamorelin, trelstar, moapar and salvacyl among others. The company offer products for the treatment of in vitro fertilization, metastatic colorectal cancer, advanced prostate cancer, precocious puberty, endometriosis, liver cancer, pancreatic cancer, uterine fibroids, severe sexual deviations and other diseases. It also develops drugs for indications in the therapeutic areas of infectious diseases and orphan drugs. The company provides licensing of products to pharmaceutical companies for marketing and sales. Debiopharm is headquartered in Lausanne, Switzerland.
Debiopharm International SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Debiopharm International SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Debiopharm International SA, Medical Devices Deals, 2012 to YTD 2018 9
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Debiopharm International SA, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 12
Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 13
Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 14
Venture Financing 16
Spinomix Raises USD 3 Million In Series A Financing 16
Biocartis Raises USD 44.7 Million In Series D Financing 17
Partnerships 19
Debiopharm Partners with Merck and Pfizer 19
Debiopharm Enters into Distribution Agreement with Arbor Pharma 20
Debiopharm International Enters into Agreement with EORTC 21
United Labs Enters into Distribution Agreement with Debiopharm International 22
Debiopharm Enters into Agreement with Solid Biosciences 23
Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 24
Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 25
Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 26
Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 27
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 28
Licensing Agreements 29
Debiopharm International Enters into Licensing Agreement with Almac Discovery 29
Evotec Enters Into Licensing Agreement With Debiopharm 30
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 31
Shasun Pharma Enters Into Licensing Agreement With Debiopharm 32
Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 33
Debiopharm International SA-Key Competitors 34
Debiopharm International SA-Key Employees 35
Debiopharm International SA-Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Government and Public Interest 37
Jul 25, 2017: Debiopharm International Awarded USD 2.6 Million Grant from CARB-X to Support Development of Debio 1453 to Fight Drug Resistant Gonorrhea 37
Clinical Trials 38
Jan 10, 2017: Debiopharm International Announces positive Phase 2 Clinical Trial with Debio 1450 in ABSSSI patients 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39
List Of Figure
List of Figures
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Debiopharm International SA, Medical Devices Deals, 2012 to YTD 2018 9
List Of Table
List of Tables
Debiopharm International SA, Pharmaceuticals & Healthcare, Key Facts 2
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Debiopharm International SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Debiopharm International SA, Deals By Therapy Area, 2012 to YTD 2018 8
Debiopharm International SA, Medical Devices Deals, 2012 to YTD 2018 9
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 12
Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 13
Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 14
Spinomix Raises USD 3 Million In Series A Financing 16
Biocartis Raises USD 44.7 Million In Series D Financing 17
Debiopharm Partners with Merck and Pfizer 19
Debiopharm Enters into Distribution Agreement with Arbor Pharma 20
Debiopharm International Enters into Agreement with EORTC 21
United Labs Enters into Distribution Agreement with Debiopharm International 22
Debiopharm Enters into Agreement with Solid Biosciences 23
Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 24
Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 25
Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 26
Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 27
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 28
Debiopharm International Enters into Licensing Agreement with Almac Discovery 29
Evotec Enters Into Licensing Agreement With Debiopharm 30
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 31
Shasun Pharma Enters Into Licensing Agreement With Debiopharm 32
Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 33
Debiopharm International SA, Key Competitors 34
Debiopharm International SA, Key Employees 35
Debiopharm International SA, Subsidiaries 36
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Debiopharm International SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020